Personal
Become a Client
Nanobiotix SA (EUR)
NANO
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range13.74 | 14.11
52-Wk Range- | -
Last Close13.83
Mkt Cap (m)476.12
Dividend yield-
ISINFR0011341205
Volume55,918.00
Exchange VenuePAR

Company Profile

Nanobiotix SA is engaged in the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action. It develops tools for cancer, which utilize a physical mode of action at the cellular level of the cancer cell.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales4,578.87
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 11/12/2020
Annual Report
en 31/12/2020

Please refer to the below issuer website for further documents.

http://www.nanobiotix.com

Financials

Income Statement
EUR201520162017201820192020
Revenue (m)0.271.560.250.120.07-
Operating Income (m)-17.14-21.85-25.27-9.17-46.78-
Net Income (m)-17.00-21.88-26.14-30.35-50.92-
Basic EPS-1.20-1.43-1.50-1.55-2.35-
Avg. Diluted Shares Outstanding (m)14.1415.2817.4819.6321.63-
Balance Sheet
EUR201520162017201820192020
Current Assets (m)22.9526.8953.1142.6546.13-
Non Current Assets (m)3.473.514.363.5410.08-
Total Assets (m)26.4230.4057.4746.2056.21-
Current Liabilities (m)7.108.259.3511.6014.35-
Total Liabilities (m)------
Total Equity (m)15.6117.4043.9214.24-1.91-
Cash Flows
EUR201520162017201820192020
Operating Cash Flows (m)-16.82-18.28-21.03-25.99-41.17-
Capital Expenditure (m)----0.51-1.44-
Figures are quoted in EUR unless stated otherwise
-
No change
13.83
Last Price